Every compound discussed here is supplied strictly as a laboratory research material. None is approved, intended or authorised for human consumption or any therapeutic use, and none is an FDA-approved medicine. The findings below are drawn from preclinical models (cell culture and animal studies) and do not establish safety or efficacy in humans. This article is written for qualified researchers and is not medical advice.
The map is bigger than the incretins
If you only read the mainstream coverage, you would think peptide science began and ended with GLP-1. The incretin agonists — semaglutide, tirzepatide and the investigational triple agonist retatrutide — have earned their attention, and if that class is what you are after, our incretin comparison covers it in depth. But the research literature is far wider. Several non-incretin peptides — molecules that have nothing to do with gut-hormone receptors — remain active, long-running subjects of preclinical study across tissue repair, mitochondrial biology, the extracellular matrix and the growth-hormone axis.
The framing matters before we start. These are research reagents, not settled treatments. Most of the data below comes from cell culture and animal models; human evidence is limited or absent, and none of these compounds is an approved medicine. With that fixed firmly in place, here is the lie of the land.
| Peptide | Class | Main research focus |
|---|---|---|
| BPC-157 | Pentadecapeptide (gastric-juice fragment) | Tissue repair, angiogenesis (VEGFR2) |
| TB-500 | Thymosin β-4 actin-binding fragment | Actin regulation, cell migration, wound models |
| MOTS-C | Mitochondrial-derived peptide (mitokine) | AMPK activation, metabolic & exercise biology |
| GHK-Cu | Copper-binding tripeptide | Skin / ECM, collagen, gene-expression studies |
| Ipamorelin | GH secretagogue (GHS-R1a agonist) | Selective, pulsatile GH release studies |
All five are investigational research compounds. None is FDA-approved or authorised for human use.
BPC-157: the tissue-repair benchmark
BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide — a 15-amino-acid fragment derived from a protein isolated in human gastric juice — and it is one of the most extensively studied tissue-repair peptides in the preclinical literature, with more than 30 years of published work behind it. Its most characterised mechanism is upregulation of the VEGFR2 receptor, which drives angiogenesis: new blood-vessel formation is a rate-limiting step in tissue repair, and BPC-157's activity here recurs across multiple animal injury models. It also engages the FAK-paxillin and JAK2/STAT3 pathways tied to fibroblast migration and matrix synthesis, and is unusually acid-stable for a peptide of its class.
Honest framing: the evidence base is almost entirely preclinical, with only small retrospective human case series. BPC-157 has not received FDA approval, was added to the FDA's Category 2 compounding list in 2023, and is prohibited under WADA. It remains a research subject — see the full BPC-157 research profile or, for material, buy BPC-157 UK.
TB-500: actin and cell migration
TB-500 is a synthetic heptapeptide corresponding to the actin-binding domain (Ac-LKKTETQ) of thymosin β-4, a protein present in virtually all nucleated mammalian cells. Its primary mechanism is G-actin sequestration: by binding monomeric actin with high affinity, it shifts the G/F-actin equilibrium that governs cell migration, division and shape — promoting the lamellipodia and filopodia that let repair cells move through tissue. It also transiently raises matrix-metalloproteinase activity to remodel the extracellular matrix. Where BPC-157 works chiefly through angiogenesis, TB-500 works through the cytoskeleton, which is why the two are often studied as mechanistically complementary; our BPC-157 vs TB-500 comparison unpacks that contrast.
The caveats mirror BPC-157: human data is very limited, the distinction between TB-500 and full thymosin β-4 matters when reading studies, and it carries FDA Category 2 and WADA-prohibited status. Full detail sits on the TB-500 research profile; research material is available if you buy TB-500 UK.
MOTS-C: a peptide written in the mitochondrial genome
MOTS-C is the genuinely novel entry here. It is a 16-amino-acid peptide encoded not by the nuclear genome but by the mitochondrial genome — discovered in 2015 (Lee et al., Cell Metabolism) and classed as a mitochondrial-derived peptide, or 'mitokine'. Its principal action is activation of AMPK, the cellular energy sensor, which in skeletal-muscle models promotes GLUT4-mediated glucose uptake and fatty-acid oxidation. Circulating MOTS-C rises with exercise and declines with age, which is why it sits at the centre of metabolic, exercise-physiology and longevity research rather than in the incretin conversation at all.
It is firmly experimental: no approved therapeutic use, WADA-prohibited as an AMPK activator, FDA-listed as a compounding safety risk, and held back clinically by delivery challenges such as low bioavailability and a short half-life. The evidence is predominantly preclinical. Read more on the MOTS-C research profile or buy MOTS-C UK for research use.
GHK-Cu: the copper tripeptide
GHK-Cu (glycyl-L-histidyl-L-lysine copper complex) is a naturally occurring copper-binding tripeptide, first isolated from human plasma in 1973 and among the most thoroughly characterised peptides in the biochemical literature. In fibroblast studies it stimulates synthesis of collagen, elastin, proteoglycans and glycosaminoglycans — the structural components of the extracellular matrix — and gene-profiling work using the Connectivity Map has reported that GHK modulates a strikingly broad gene set, including DNA-repair and antioxidant genes. That transcriptomic breadth is a large part of why a single small tripeptide draws so much research interest in skin and ECM biology.
As ever, framing matters: the dermatological and wound-model data come from controlled research settings and do not constitute approval for cosmetic or therapeutic use, and injectable GHK-Cu was added to the FDA's Category 2 compounding list in 2023. See the GHK-Cu research profile or buy GHK-Cu UK.
Ipamorelin: a selective GH secretagogue
Rounding out the tour is a growth-hormone secretagogue. Ipamorelin is a synthetic pentapeptide and a selective agonist of the ghrelin receptor (GHS-R1a) on pituitary somatotrophs, where it triggers a discrete, pulsatile release of growth hormone. Its distinguishing feature — established in the landmark 1998 Raun et al. study — is selectivity: it drives GH release without the cortisol, ACTH or prolactin co-stimulation seen with earlier GHRPs, even at doses far above its GH-releasing threshold. That clean profile makes it a useful tool where isolated GH-axis stimulation is the research question, and it is frequently studied alongside GHRH analogues such as CJC-1295.
Ipamorelin has no FDA approval for any indication, the FDA has flagged immunogenicity concerns with compounded GHS peptides, and it is WADA-prohibited as a peptide hormone. The Ipamorelin research profile has the mechanism in full, and research material is available if you buy Ipamorelin UK.
The bottom line
The GLP-1 story is real, but it is one region of a much larger map. BPC-157 and TB-500 anchor the tissue-repair literature through angiogenesis and actin biology respectively; MOTS-C brings a genuinely new class — a peptide encoded in the mitochondria — to metabolic and longevity research; GHK-Cu remains a workhorse of skin and ECM study; and Ipamorelin offers a clean, selective handle on the GH axis. What unites them is not a shared mechanism but a shared status: these are research subjects, not treatments. The data is largely preclinical, none is FDA-approved, and all are supplied strictly for in vitro use. Treated that way — as reagents for well-designed experiments — they are among the more interesting compounds in the field right now. Browse them all in the knowledgebase.
